(Q38370696)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25752480%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

review article

1 reference

title

Translational psychiatry--light at the end of the tunnel (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25752480%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25752480%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

author name string

Kenneth A Jones

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25752480%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Digavalli V Sivarao

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25752480%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

language of work or name

English

0 references

publication date

9 March 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25752480%20AND%20SRC:MED&resulttype=core&format=json

Annals of the New York Academy of Sciences

2 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25752480%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

volume

1344

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25752480%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

page(s)

1-11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25752480%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12725

Pathways to new drug discovery in neuropsychiatry

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12725

Translating discoveries into medicine: psychiatric drug development in 2011.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12725

Biomarkers in psychiatry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12725

National Institute of Mental Health clinical trials: new opportunities, new expectations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12725

Copy number variations in neurodevelopmental disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12725

Removing obstacles in neuroscience drug discovery: the future path for animal models

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12725

Genome-wide association studies: findings at the major histocompatibility complex locus in psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12725

Specific and common genes implicated across major mental disorders: a review of meta-analysis studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12725

Recent genetic findings in schizophrenia and their therapeutic relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12725

From psychiatric disorders to animal models: a bidirectional and dimensional approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12725

Developing predictive CSF biomarkers-a challenge critical to success in Alzheimer's disease and neuropsychiatric translational medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12725

A role for fMRI in optimizing CNS drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12725

Longitudinal associations between mismatch negativity and disability in early schizophrenia- and affective-spectrum disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12725

Automatic auditory processing deficits in schizophrenia and clinical high-risk patients: forecasting psychosis risk with mismatch negativity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12725

Fundamentals of electroencefalography, magnetoencefalography, and functional magnetic resonance imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12725

Discovery of blood transcriptomic markers for depression in animal models and pilot validation in subjects with early-onset major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12725

Blood transcriptomic biomarkers in adult primary care patients with major depressive disorder undergoing cognitive behavioral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12725

Blood transcriptomic markers for major depression: from animal models to clinical settings.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12725

A roadmap for the development and validation of event-related potential biomarkers in schizophrenia research

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12725

Aligning strategies for using EEG as a surrogate biomarker: a review of preclinical and clinical research.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12725

Electroencephalogram effect measures and relationships between pharmacokinetics and pharmacodynamics of centrally acting drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12725

Advances in quantitative electroencephalogram analysis methods.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12725

Neuronal oscillations in cortical networks

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12725

The intrinsic electrophysiological properties of mammalian neurons: insights into central nervous system function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12725

Bursting of thalamic neurons and states of vigilance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12725

The effects of subcortical lesions on evoked potentials and spontaneous high frequency (gamma-band) oscillating potentials in rat auditory cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12725

Chattering cells: superficial pyramidal neurons contributing to the generation of synchronous oscillations in the visual cortex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12725

Thalamic modulation of high-frequency oscillating potentials in auditory cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12725

Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12725

Electroencephalographic effects of benzodiazepines. II. Pharmacodynamic modeling of the electroencephalographic effects of midazolam and diazepam.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12725

Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12725

Effects of phencyclidine (PCP) and MK 801 on the EEGq in the prefrontal cortex of conscious rats; antagonism by clozapine, and antagonists of AMPA-, alpha(1)- and 5-HT(2A)-receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12725

Pharmacodynamic modeling of the electroencephalographic effects of flumazenil in healthy volunteers sedated with midazolam.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12725

NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12725

N-methyl d-aspartate receptor antagonists ketamine and MK-801 induce wake-related aberrant gamma oscillations in the rat neocortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12725

A critical role for NMDA receptors in parvalbumin interneurons for gamma rhythm induction and behavior.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12725

Postnatal development of NR1, NR2A and NR2B immunoreactivity in the visual cortex of the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12725

Neuronal and glial localization of NR1 and NR2A/B subunits of the NMDA receptor in the human cerebral cortex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12725

Laminar distribution of NMDA receptor subunit (NR1, NR2A, NR2B) expression during the critical period in cat visual cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12725

The novel α7 nicotinic acetylcholine receptor agonist EVP-6124 enhances dopamine, acetylcholine, and glutamate efflux in rat cortex and nucleus accumbens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12725

Effect of R3487/MEM3454, a novel nicotinic alpha7 receptor partial agonist and 5-HT3 antagonist on sustained attention in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12725

Target site occupancy: emerging generalizations from clinical and preclinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12725

Low sensitivity of the positron emission tomography ligand [11C]diprenorphine to agonist opiates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12725

Metabotropic glutamate receptors: physiology, pharmacology, and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12725

Glutamate receptor ion channels: structure, regulation, and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12725

Synaptic plasticity: multiple forms, functions, and mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12725

NMDA receptor subunits: diversity, development and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12725

NMDA-receptor-dependent synaptic plasticity: multiple forms and mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12725

Phencyclidine/schizophrenia: one view toward the past, the other to the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12725

Has an angel shown the way? Etiological and therapeutic implications of the PCP/NMDA model of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12725

NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12725

Translating glutamate: from pathophysiology to treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12725

NMDA receptor hypofunction model of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12725

Recent advances in the phencyclidine model of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12725

Genetic risk for schizophrenia: convergence on synaptic pathways involved in plasticity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12725

Capturing the angel in "angel dust": twenty years of translational neuroscience studies of NMDA receptor antagonists in animals and humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12725

Antidepressant effects of ketamine in depressed patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12725

A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12725

Ketamine for depression: where do we go from here?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12725

Cracking the moody brain: lifting the mood with ketamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12725

Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12725

Signaling pathways underlying the rapid antidepressant actions of ketamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12725

Activation of mammalian target of rapamycin and synaptogenesis: role in the actions of rapid-acting antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12725

Synaptic mechanisms underlying rapid antidepressant action of ketamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12725

mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12725

Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12725

Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12725

In pursuit of neuroimaging biomarkers to guide treatment selection in major depressive disorder: a review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12725

Neurophysiological models for new treatment development in schizophrenia: early sensory approaches.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12725

Ketamine as a promising prototype for a new generation of rapid-acting antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12725

EEG biomarkers of target engagement, therapeutic effect, and disease process

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12725

Rhythms and blues: modulation of oscillatory synchrony and the mechanism of action of antidepressant treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12725

NMDA receptor hypofunction produces concomitant firing rate potentiation and burst activity reduction in the prefrontal cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12725

Differential role of NR2A and NR2B subunits in N-methyl-D-aspartate receptor antagonist-induced aberrant cortical gamma oscillations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12725

Synaptic potentiation is critical for rapid antidepressant response to ketamine in treatment-resistant major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12725

Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12725

Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12725

Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12725

NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12725

CP-101,606: An NR2B-Selective NMDA Receptor Antagonist.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12725

An open-label study of CP-101,606 in subjects with a severe traumatic head injury or spontaneous intracerebral hemorrhage

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12725

A double-blind, placebo-controlled study of the safety, tolerability and pharmacokinetics of CP-101,606 in patients with a mild or moderate traumatic brain injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12725

Effects of a NR2B selective NMDA glutamate antagonist, CP-101,606, on dyskinesia and Parkinsonism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12725

An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12725

NR2B Antagonist CP-101,606 Abolishes Pitch-Mediated Deviance Detection in Awake Rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12725

Developmental origin dictates interneuron AMPA and NMDA receptor subunit composition and plasticity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12725

21 January 2018

Identifiers

DOI

10.1111/NYAS.12725

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25752480%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

1 reference